{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T21:40:27Z","timestamp":1727127627514},"reference-count":5,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bulcan.2024.06.009","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T11:26:20Z","timestamp":1725276380000},"page":"906-908","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retifanlimab dans le carcinome de Merkel m\u00e9tastatique en premi\u00e8re ligne"],"prefix":"10.1016","volume":"111","author":[{"given":"Clara","family":"Zucman-Rossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Boussemart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bulcan.2024.06.009_bib0030","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2017.10.028","article-title":"Merkel cell carcinoma: current US incidence and projected increases based on changing demographics","volume":"78","author":"Paulson","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.bulcan.2024.06.009_bib0035","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1200\/JCO.2005.02.329","article-title":"Merkel cell carcinoma: prognosis and treatment of patients from a single institution","volume":"23","author":"Allen","year":"2005","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.bulcan.2024.06.009_bib0040","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2217\/fon-2017-0072","article-title":"Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma","volume":"13","author":"Nghiem","year":"2017","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2024.06.009_bib0045","doi-asserted-by":"crossref","first-page":"100529","DOI":"10.1016\/j.esmoop.2022.100529","article-title":"A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)","volume":"7","author":"Rao","year":"2022","journal-title":"ESMO Open"},{"year":"2023","series-title":"Updated results from POD1UM-201: a phase 2\u00a0study of retifanlimab in patients with advanced or metastatic Merkel cell","author":"Grignani","key":"10.1016\/j.bulcan.2024.06.009_bib0025"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124002686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124002686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T21:05:27Z","timestamp":1727125527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124002686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":5,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0007455124002686"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.06.009","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retifanlimab dans le carcinome de Merkel m\u00e9tastatique en premi\u00e8re ligne","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}